Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Sarcoma 10Sarcoma, Alveolar Soft Part 3Breast Neoplasms 3Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Gliosarcoma 2Glioblastoma 2Vulvar Neoplasms 1Urogenital Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Obesity 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lung Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Oxaliplatin 2Observation 2Leucovorin 2Irinotecan 2Ipilimumab 2Cisplatin 2tivozanib 1spartalizumab 1seribantumab 1pembrolizumab 1motexafin lutetium 1entinostat 1atezolizumab 1Thalidomide 1Specimen Handling 1Quality of Life 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Paclitaxel 1Octreotide 1Nivolumab 1Molecular Diagnostic Techniques 1Mesna 1Magnetic Resonance Spectroscopy 1Immunotherapy 1Ifosfamide 1Fluorouracil 1Floxuridine 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × atezolizumab × Sarcoma × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡